2 Clarke Drive
Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Dr Pro outlines the current role of duvelisib in peripheral T-cell lymphoma (PTCL), reviews some key adverse effects associated with the agent, and walks us through other important updates in PTCL presented at the 2021 ASH Annual Meeting and Exposition.
Welcome to OncLive On Air®! I’m your host today, Caroline Seymour.
OncLive On Air® is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive® covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.
In today’s episode, sponsored by Secura Bio, we had the pleasure of speaking with Barbara Pro, MD, a clinician, researcher, and professor of medicine in the Division of Hematology and Oncology at Columbia University Vagelos College of Physicians and Surgeons, and the clinical director of the lymphoma program at the Herbert Irving Comprehensive Cancer Center at NewYork-Presbyterian/Columbia University Irving Medical Center. Pro highlighted results presented at the 2021 ASH Annual Meeting and Exposition from a trial assessing duvelisib (Copiktra) for patients with relapsed/refractory peripheral T-cell lymphoma (PTCL).
In March 2022, the National Comprehensive Cancer Network (NCCN) updated its Clinical Practice Guidelines in Oncology to include duvelisib as a category 2A-designated option for second-line and later treatment in relapsed/refractory PTCL.
The phase 2 PRIMO trial (NCT03372057) is currently assessing dose-optimization and dose-expansion of duvelisib in this patient population. Investigators presented an updated analysis from trial confirming the activity of duvelisib in December 2021.
In our exclusive interview, Dr Pro outlined the current role of duvelisib in PTCL, reviewed some key adverse effects (AEs) associated with the agent, and walked us through other important updates in PTCL presented at ASH.
That’s all we have for today! Thank you for listening to this episode of OncLive On Air®, sponsored by Secura Bio. Check back on Mondays and Thursdays for exclusive interviews with leading experts in the oncology field.
For more updates in oncology, be sure to visit www.OncLive.com and sign up for our e-newsletters.
OncLive® is also on social media. On Twitter, follow us at @OncLive and @OncLiveSOSS. On Facebook, like us at OncLive and OncLive State of the Science Summit and follow our OncLive page on LinkedIn.
If you liked today’s episode of OncLive On Air®, please consider subscribing to our podcast on Apple Podcasts, Spotify, Google Podcasts, Amazon Music, and many of your other favorite podcast platforms,* so you get a notification every time a new episode is posted. While you are there, please take a moment to rate us!
Thanks again for listening to OncLive On Air®.
*OncLive On Air® is available on: Apple Podcasts, Google Podcasts, Spotify, Amazon Music, Audacy, CastBox, Deezer, iHeart, JioSaavn, Listen Notes, Player FM, Podcast Addict, Podchaser, RadioPublic, and TuneIn.